Teva Announces Presentation of New Data on Multiple Sclerosis and Parkinson's Disease Treatments

Teva Pharmaceutical Industries Ltd. TEVA today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products. More than 30 posters, including a late-breaking presentation on data from the pivotal Phase III trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis, will be unveiled at the 63rd American Academy of Neurology Annual Meeting in Honolulu, HI, April 9-16, 2011.